230 related articles for article (PubMed ID: 33809082)
1. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
[TBL] [Abstract][Full Text] [Related]
2. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
3. Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
Giovannelli I; Martelli F; Repice A; Massacesi L; Azzi A; Giannecchini S
J Neurovirol; 2015 Dec; 21(6):666-70. PubMed ID: 25678142
[TBL] [Abstract][Full Text] [Related]
4. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
5. COS-7 cells are a cellular model to monitor polyomavirus JC miR-J1-5p expression.
Agostini S; Mancuso R; Costa AS; Guerini FR; Clerici M
Mol Biol Rep; 2020 Nov; 47(11):9201-9205. PubMed ID: 33085050
[TBL] [Abstract][Full Text] [Related]
6. High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
Takahashi K; Sato Y; Sekizuka T; Kuroda M; Suzuki T; Hasegawa H; Katano H
PLoS Pathog; 2020 Apr; 16(4):e1008523. PubMed ID: 32324824
[TBL] [Abstract][Full Text] [Related]
7. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
8. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
Viruses; 2016 May; 8(5):. PubMed ID: 27164128
[TBL] [Abstract][Full Text] [Related]
9. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
10. Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Rossi F; Prosperini L; De Rossi N; Capra R; Rivanera D; Li X; Cinque P; Passeri L; Pozzilli C; Viscidi R
Viral Immunol; 2017 Oct; 30(8):622-626. PubMed ID: 28836899
[TBL] [Abstract][Full Text] [Related]
11. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
[TBL] [Abstract][Full Text] [Related]
12. Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
Villani S; Zanotta N; Ambrogi F; Comar M; Franciotta D; Dolci M; Cason C; Ticozzi R; Ferrante P; Delbue S
J Neuroimmunol; 2017 Sep; 310():91-96. PubMed ID: 28778452
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
Prezioso C; Ciotti M; Brazzini G; Piacentini F; Passerini S; Grimaldi A; Landi D; Nicoletti CG; Zingaropoli MA; Iannetta M; Altieri M; Conte A; Limongi D; Marfia GA; Ciardi MR; Mastroianni CM; Palamara AT; Moens U; Pietropaolo V
J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054041
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
15. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
16. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
19. The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML.
Rocca A; Martelli F; Delbue S; Ferrante P; Bartolozzi D; Azzi A; Giannecchini S
J Clin Virol; 2015 Sep; 70():1-6. PubMed ID: 26305810
[TBL] [Abstract][Full Text] [Related]
20. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]